I rate STEW a buy for its strong earnings, solid dividend coverage, and attractive 20% discount to NAV, offering compelling ...

Cogent Biosciences (NASDAQ:COGT) has announced the pricing of its previously disclosed underwritten public offering of 22,222,223 shares of its common stock at $9.00 per share, for expected gross ...